Stifel downgraded Novo Nordisk A/S from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $64.00 | Outperform → Market Perform | BMO Capital Markets |
| 3/13/2025 | Hold → Buy | Kepler | |
| 3/3/2025 | Buy → Hold | Stifel | |
| 2/12/2025 | Equal-Weight | Morgan Stanley | |
| 1/6/2025 | Underperform → Mkt Perform | Bernstein | |
| 5/30/2024 | $156.00 | Buy | Goldman |
| 4/12/2024 | $163.00 | Outperform | BMO Capital Markets |
| 1/23/2024 | $120.00 | Overweight | Morgan Stanley |
BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00
Kepler upgraded Novo Nordisk A/S from Hold to Buy
Stifel downgraded Novo Nordisk A/S from Buy to Hold
The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choicePLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy® was only available via the recently launched NovoCare® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them acces
NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverageAmidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare® Pharmacy offers reliable access to authentic, FDA-approved Wegovy® in our once-weekly, single-dose pen PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access i
MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE:NVO). As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account. This provides a unique tool for tactical traders. NVOX does not invest directly in Novo Nordisk and has a higher degree of risk due to tracking a single stock. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, seeking to
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr